Chief Financial Officer and Treasurer (until May 1, 2022) · Denali Therapeutics Inc. (DNLI)

Steve Krognes

A named executive officer of Denali Therapeutics in every fiscal year CompBrief holds from FY2017 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$4,286,877

Salary $167,067Stock awards $1,465,370

FY2021: $6,587,660

4th of 4 named executive officers at Denali Therapeutics by FY2022 total.

4 named officers on file for Denali Therapeutics, FY2022

Steve Krognes’s pay file — $29

  • 6 fiscal years of pay, line by line
  • 9 equity grants, each cited to its filing
  • DNLI’s disclosed peer group of 23 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Denali Therapeutics’s whole pay program stands against its peers

  • Denali Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on DNLI→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 18, 2023 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Steve Krognes’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Steve Krognes compensation by year

Denali Therapeutics Summary Compensation Table · all 6 fiscal years held
In US dollars, as Denali Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018FY2019FY2020FY2021FY2022
Salary$437,750$455,260$470,057$484,200$501,150$167,067
Bonus$218,875$393,682$188,023$387,362$300,690$0
Stock awards$0$179,673$305,830$1,364,638$2,125,800$1,465,370
Option awards$497,350$2,948,616$1,558,941$2,018,444$3,648,420$2,647,757
Non-equity incentive$0$0$0$0$0$0
Pension and deferred compensation$0$0$0$0$0$0
All other$12,585$24,000$7,834$11,400$11,600$6,683
Total$1,166,560$4,001,231$2,530,685$4,266,044$6,587,660$4,286,877

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Denali Therapeutics Inc. DEF 14A filed April 18, 2023, accession 0001714899-23-000062, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Denali Therapeutics Inc. filed document, accession 0001714899-23-000062. Every figure is read from that document and cited to the page and table it appears in. Filed April 18, 2023.

$1.2M
$4.0M
$2.5M
$4.3M
$6.6M
$4.3M
FY17
FY18
FY19
FY20
FY21
FY22
SalaryBonusStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
RSU22,500$625,725—
RSU14,572$405,247—
RSU10,000$278,100—
RSU4,250$118,193—
Option39,668—$24.81
Option46,876—$70.86
Option5,669—$17.99

Per the Outstanding Equity Awards at Fiscal Year-End table in Denali Therapeutics Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

19 Form 4 lines since the FY2022 proxy (filed April 18, 2023)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-06-03Grant or award—6,408$0.0038,202
2026-06-03Grant or award derivative—19,226$0.0019,226
2025-06-03Grant or award—6,037$0.0031,794
2025-06-03Grant or award derivative—18,111$0.0018,111
2025-01-07Sale—3,339$20.8125,757
2024-12-31Sale10b5-130,000$20.2529,096
2024-09-30Sale10b5-130,000$29.0329,096
2024-08-20Sale—1,727$23.7932,677

The 8 most recent of 19 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Denali Therapeutics’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Ryan WattsPresident and Chief Executive Officer$9,284,688
Carole HoChief Medical Officer$5,692,052
Alexander SchuthChief Operating and Financial Officer and Secretary$5,692,052
Steve Krognes · this pageChief Financial Officer and Treasurer (until May 1, 2022)$4,286,877

Board service

Denali Therapeutics board · FY2022–FY2025
Director compensation in US dollars, as Denali Therapeutics reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$55,769$84,095$157,285$0$297,149
FY2024$45,000$110,748$203,717—$359,465
FY2023$45,000$130,359$244,075—$419,434
FY2022$30,021$0$0—$30,021

Each year as the company reported it in Denali Therapeutics's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: Denali Therapeutics pays directors a $50,000 cash retainer. As stated in Denali Therapeutics's FY2025 proxy.

Committees

Audit

The full Denali Therapeutics compensation record

free company brief

This page is one person within Denali Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Denali Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Denali Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Steve Krognes's compensation dossier · One-time report. No refunds.